UBS Group
TMCI icon

UBS Group’s Treace Medical Concepts TMCI Stock Holding History

UBS Group’s Portfolio TMCI Stock Details TMCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Sell
366,445
-176,460
-33% -$485K ﹤0.01% 5399
2026
Q1 		$727K Buy
542,905
+248,976
+85% +$496K ﹤0.01% 5798
2025
Q4 		$720K Buy
293,929
+10,580
+4% +$45.9K ﹤0.01% 5841
2025
Q3 		$1.9M Sell
283,349
-94,098
-25% -$614K ﹤0.01% 5000
2025
Q2 		$2.22M Buy
377,447
+16,128
+4% +$105K ﹤0.01% 4704
2025
Q1 		$3.03M Sell
361,319
-607,115
-63% -$5.46M ﹤0.01% 4306
2024
Q4 		$7.21M Buy
968,434
+892,456
+1,175% +$5.97M ﹤0.01% 3422
2024
Q3 		$441K Buy
75,978
+35,959
+90% +$231K ﹤0.01% 5319
2024
Q2 		$266K Sell
40,019
-44,684
-53% -$361K ﹤0.01% 5466
2024
Q1 		$1.11M Buy
84,703
+32,904
+64% +$439K ﹤0.01% 4523
2023
Q4 		$660K Buy
51,799
+51,674
+41,339% +$522K ﹤0.01% 4853
2023
Q3 		$1.64K Sell
125
-33,199
-100% -$608K ﹤0.01% 7873
2023
Q2 		$852K Buy
33,324
+19,179
+136% +$495K ﹤0.01% 4385
2023
Q1 		$356K Buy
14,145
+8,039
+132% +$189K ﹤0.01% 4952
2022
Q4 		$140K Buy
6,106
+4,664
+323% +$107K ﹤0.01% 5778
2022
Q3 		$32K Buy
1,442
+637
+79% +$12.3K ﹤0.01% 6804
2022
Q2 		$11K Buy
805
+705
+705% +$11.9K ﹤0.01% 7848
2022
Q1 		$2K Sell
100
-9,435
-99% -$183K ﹤0.01% 9674
2021
Q4 		$178K Buy
9,535
+9,311
+4,157% +$192K ﹤0.01% 5802
2021
Q3 		$6K Sell
224
-251
-53% -$6.91K ﹤0.01% 8451
2021
Q2 		$15K Buy
+475
New +$15.1K ﹤0.01% 7650

Other funds holding TMCI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GA
Gagnon Advisors New York $157M AUM 36.77% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $82.3B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

UBS Group's TMCI Position: Q2 2026 in Review

UBS Group reduced its Treace Medical Concepts (TMCI) stake by 33% in Q2 2026, selling an estimated $485K and leaving 366,445 shares worth $1.46M. The position accounts for ﹤0.01% of the portfolio, ranked #5399.

UBS Group first reported a position in TMCI in Q2 2021 and has held it in 21 quarters since. The position peaked at $7.21M in Q4 2024. 117 funds tracked by Wall St. Rank hold TMCI as of Q2 2026.

  • UBS Group held 366,445 shares of Treace Medical Concepts worth $1.46M as of Q2 2026.
  • UBS Group sold 176,460 Treace Medical Concepts shares in Q2 2026, an estimated $485K.
  • Treace Medical Concepts made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5399 holding.
  • UBS Group first reported a position in Treace Medical Concepts in Q2 2021 and has held it in 21 quarters since.
  • UBS Group's Treace Medical Concepts position peaked at $7.21M in Q4 2024.
  • 117 funds tracked by Wall St. Rank held Treace Medical Concepts as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.